Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

Pomerantz LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until September 24, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired MacroGenics securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On May 9, 2024, MacroGenics issued a press release disclosing the deaths of five patients in the Company’s Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) in patients with metastatic astration. 

On this news, MacroGenics’ stock price fell $11.36 per share, or 77.4%, to close at $3.31 per share on May 10, 2024.